NovoCure Aktie

10,45 EUR +0,46 EUR +4,65 %

21.11.2025

BMN

11,94 USD +0,48 USD +4,14 %

nachbörslich21.11.2025

BTT

NovoCure jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.1,11 Mrd. EUR

Div. Rendite0,00%

WKNA140ML

ISINJE00BYSS4X48

SymbolNVCR

NovoCure Aktien News

Sortieren:Datum Meistgelesen

13.01.25BusinesswireNovocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

03.01.25BusinesswireNovocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

05.12.24BusinesswireNovocure gibt positive Ergebnisse der Phase-3-Studie PANOVA-3 zur Tumor Treating Fields (TTFields)-Therapie bei Bauchspeicheldrüsenkrebs bekannt

WerbungNovoCure-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

02.12.24BusinesswireNovocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

27.11.24BusinesswireNovocure to Participate in Upcoming Investor Conferences

21.11.24BusinesswireNovocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

21.11.24BusinesswireFDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

31.10.24BusinesswireNovocure meldet Finanzergebnisse des dritten Quartals 2024

31.10.24BusinesswireNovocure ernennt Christoph Brackmann zum Finanzvorstand

30.10.24BusinesswireNovocure Appoints Christoph Brackmann as Chief Financial Officer

30.10.24BusinesswireNovocure Reports Third Quarter 2024 Financial Results

22.10.24BusinesswireFDA genehmigt Optune Lua® von Novocure zur Behandlung des metastasierenden nicht-kleinzelligen Lungenkarzinoms

15.10.24BusinesswireFDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

01.10.24BusinesswireNovocure to Report Third Quarter 2024 Financial Results

09.09.24BusinesswireNovocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

03.09.24BusinesswireNovocure Announces Planned CEO Transition

28.08.24BusinesswireNovocure to Participate in 2024 Wells Fargo Healthcare Conference

14.08.24BusinesswireNovocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

25.07.24BusinesswireNovocure Reports Second Quarter 2024 Financial Results

01.07.24BusinesswireNovocure to Report Second Quarter 2024 Financial Results

03.06.24BusinesswireMETIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

24.05.24BusinesswireTIGER-Studie berichtet über neue Überlebensergebnisse der TTFields-Therapie bei neu diagnostizierten Glioblastom-Patienten in Deutschland

02.05.24BusinesswireNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

02.05.24BusinesswireNovocure Reports First Quarter 2024 Financial Results

01.04.24BusinesswireNovocure to Report First Quarter 2024 Financial Results

11.03.24BusinesswireINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

22.02.24BusinesswireNovocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

18.01.24BusinesswireNovocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

09.01.24BusinesswireNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

08.01.24BusinesswireNovocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

04.01.24BusinesswireNovocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

27.12.23BusinesswireNovocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

28.11.23BusinesswireNovocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

21.11.23BusinesswireNovocure to Participate in 35th Annual Piper Sandler Healthcare Conference

10.11.23BusinesswireNovocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

26.10.23BusinesswireNovocure Reports Third Quarter 2023 Financial Results

16.10.23BusinesswireNovocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

12.10.23BusinesswireNovocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

29.09.23BusinesswireNovocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

08.09.23BusinesswireNovocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

NovoCure News

NovoCure News: auf dieser Seite finden Sie alle NovoCure News und Nachrichten zur NovoCure Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch NovoCure News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um NovoCure News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.